tovecimig
Generic: Tovecimig·Code: CTX-009
tovecimig: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Compass Therapeutics, Inc. (CMPX) | Phase 3 |
FDA Decisions
FDA_MeetingFDA granted Fast Track Designation for CTX-009 plus paclitaxel for treatment of patients with biliary tract cancer.(CMPX)
Frequently asked questions
Who is developing tovecimig?
tovecimig is being developed by Compass Therapeutics, Inc..
What is tovecimig's latest FDA decision?
The most recent tracked FDA decision for tovecimig is FDA_Meeting for FDA granted Fast Track Designation for CTX-009 plus paclitaxel for treatment of patients with biliary tract cancer., dated April 25, 2024.
Get deeper analysis on tovecimig
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis